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Liraglutide restores chronic ER 
stress, autophagy impairments and 
apoptotic signalling in SH-SY5Y 
cells
Theodora Panagaki, Maria Michael & Christian Hölscher
Growing evidence suggests that agonists of glucagon-like peptide (GLP-1) receptor exert 
neuroprotective and neurorestorative effects across a range of experimental models of neuronal 
degeneration, and, recently, a pilot clinical trial of Liraglutide in Alzheimer’s disease patients showed 
improvements in cerebral glucose consumption that signifies disease progression. However, the 
exact underlying mechanism of action remains unclear. Chronic endoplasmic reticulum (ER) stress 
has recently emerged as a mechanism for neuronal injury, rendering it a potent therapeutic target 
for acute and chronic neurodegenerative disorders. Here, we investigate the neuroprotective 
effects of Liraglutide along with the signalling network against prolong ER stress and autophagy 
impairments induced by the non-competitive inhibitor of sarco/ER Ca2+-ATPase, thapsigargin. We 
show that Liraglutide modulates the ER stress response and elicits ER proteostasis and autophagy 
machinery homeostasis in human SH-SY5Y neuroblastoma cell line. These effects correlate with 
resolution of hyper-activity of the antioxidant Nrf2 factor and restoration of the impaired cell viability 
and proliferation. Mechanistically, Liraglutide engages Akt and signal transducer and activator of 
transcription 3 (STAT3) signalling to favour adaptive responses and shift cell fate from apoptosis to 
survival under chronic stress conditions in SH-SY5Y cells.
Neuronal injury owing to chronic stress of the endoplasmic reticulum (ER) is increasingly being recognised as a 
common contributor to amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s disease (PD), 
ischaemic stroke and traumatic brain injury (TBI)1–5. Shared among these seemingly dissimilar neurological 
disorders is the presence of intracellular and/or extracellular conditions that perturb signalling and handling 
of calcium, protein folding processes and autophagic machinery, generating a vicious circle of irremediable ER 
stress1–5. The ER is a multifunctional signalling organelle that orchestrates calcium homeostasis and metabolic 
processes, including gluconeogenesis and the biosynthesis of autophagosomes in the cell. It additionally is the 
fundamental intracellular compartment for the synthesis, maturation, quality control and delivery of the secre-
tory and membrane proteins6. Much physiological and pathological stimuli can alter the protein folding at the 
ER, triggering a rise in the unfolded or misfolded protein load in the organelle lumen, a cellular state referred to 
as ER stress7. In turn, the cell activates an adaptive signalling network, known as the unfolded protein response 
(UPR). The UPR essentially engages the three ER-resident transmembrane stress transducers – protein kinase 
RNA-like ER kinase (PERK), activating transcription factor 6 (ATF6) and inositol-requiring enzyme 1 (IRE1) – 
to safeguard proteostasis through attenuation of global protein synthesis and transcriptional induction of genes 
functioning as ER chaperones, and degrade the abnormal through the proteasome (ER-associated degradation) 
and lysosome-mediated autophagy2,6,8. However, under persistent and unsurmountable ER stress, the UPR adapts 
its dynamics and drives cells towards suicide through diverse but often overlapping mechanisms, including the 
induction of proteases, kinases, the transcription of CAAT/enhancer-binding protein (C/EBP) homologous pro-
tein (CHOP) and Bcl-2 family members along with their mediators6,8. It is therefore intuitive that therapeutic 
interventions which resolve UPR and promote a balance between protein generation and degradation crucial for 
proteostasis may significantly benefit the clinical outcome of acute and chronic neurodegenerative disorders1,3–5. 
In this regard, we have focused our research efforts on investigating the restorative effects of the neuroprotective 
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glucagon-like peptide 1 (GLP-1) analogue Liraglutide against chronic ER stress and autophagy dysfunction in 
SH-SY5Y neuroblastoma cell line.
The incretin hormone GLP-1 is best known for regulating glucose homeostasis and insulin signalling and bio-
synthesis in response to food ingestion. As such, GLP-1 mimetics are currently approved for the treatment of type 
2 diabetes mellitus (T2DM). Apart from their glucose-dependent pancreatic effects, GLP-1 mimetics cross the 
blood brain barrier and modulate multiple cellular processes within the central nervous system (CNS), including 
synaptogenesis, neuronal energetics, memory formation and inflammatory responses9,10. For instance, intraperi-
toneal administration of Liraglutide has rescued cognitive and synaptic plasticity deficits, halted excessive syn-
aptic loss, enhanced mitochondria biogenesis and clearance of aggregated proteins and/or mitigated microglia 
activation and inflammation in a transgenic APP/PS1 mouse model of AD11,12, in a 1-methyl-4-phenyl-1,2,3,6
-tetrahydropyridine (MPTP) model of PD13, in a transgenic mouse model of dementia-related tauopathy14, in a rat 
model of middle cerebral artery occlusion15,16, and in a mouse model of mild TBI17. In line with the in-vivo data, 
Liraglutide and other GLP-1 mimetics have protected cultured neurons and neuronal cell lines from hypoxia, 
oxidative stress and excitotoxic injury17–21. Notably, in a pilot clinical trial, Liraglutide has rescued the decline of 
cerebral glucose consumption in AD patients, which signifies energy metabolism in brain areas that have been 
correlated with cognitive decline in AD and therefore disease progression22. Additionally, a pilot open-label clinical 
trial of the GLP-1 analogue Exenatide has demonstrated persistent improvements in cognitive and motor function 
of Parkinson’s patients23,24. A recently-published phase II placebo-controlled double-blind trial has similarly shown 
that Exenatide halts PD progression and thus confirmed the aforementioned preliminary data25. The neuropro-
tective effects of GLP-1 mimetics lie downstream of the induction of the GLP-1 receptors (GLP-1Rs)9,10. Indeed, 
GLP-1R overexpression in hippocampus augments spatial learning and memory performance in vivo, effects that 
are blocked in the presence of a GLP-1R antagonist26. Conversely, GLP-1R-deficient mice feature impaired hip-
pocampal synaptic plasticity27 accompanied by decrements in associative contextual26 and spatial learning27, and 
increased susceptibility to kainic acid-induced seizures and neuronal degeneration in the hippocampus26, as com-
pared to wild-type controls. GLP-1Rs are widely expressed in the brain and mediate survival and trophic signals 
via the Gα-protein, culminating into the stimulation of adenyl cyclase, Akt and mitogen-activated protein kinase 
(MAPK) pathways9,10. However, whether GLP-1R agonists regulate highly conserved cellular mechanisms, such as 
the UPR and protein quality control machinery, and engage additional signalling pathways to the aforementioned 
to promote neuronal survival and tissue repair remains largely unexplored.
Here we show that chronic Liraglutide treatment modulates UPR signalling, restores ER proteostasis, and 
promotes autophagic machinery homeostasis to shift cell fate from apoptosis to survival in the SH-SY5Y human 
neuroblastoma cells. To gain an integrated view of the Liraglutide-induced neuroprotection following aberrant 
ER stress and autophagy response, we correlate these effects to the antioxidant defensive Nrf2 factor activity and 
the intracellular signalling ‘pool’. In line with previous findings, we report that the GLP-1R stimulation induces 
Akt to favour adaptive responses following cellular stress. Our study further unravels that the signal transducer 
and activator of transcription 3 (STAT3) mediates survival signals downstream of GLP-1R stimulation upon irre-
mediable neuronal ER stress. Taken together, our findings provide additional evidence for the beneficial effects of 
GLP-1R signalling in neurodegenerative disorders and deepen our understanding of the underlying mechanism.
Results
Liraglutide rescues thapsigargin-induced cytotoxicity and cell-growth arrest. First, we elu-
cidated the cytoprotective effect of Liraglutide in the SH-SY5Y human neuroblastoma cells from chronic ER 
stress by thapsigargin. Thapsigargin is a naturally occurring sesquiterpene lactone that selectively inhibits sar-
coplasmic/ER Ca2+–ATPase (SERCA), triggering a transient increase in the cytosolic calcium and depleting ER 
calcium stores28. Cells were treated with 0, 10, 100 and 1000 nM of thapsigargin in the presence or absence of 
100 nM Liraglutide for 16 h, and processed for XTT, BrdU and LDH assays to assess cell viability, proliferation 
and cytotoxicity, respectively. One-way ANOVA analysis reveals overall significant differences in cell viability 
(F(7,442) = 79.59, p ≤ 0.001), proliferation (F(7,355) = 48.98, p ≤ 0.001) and cytotoxicity (F(7,436) = 255.2, p ≤ 0.001). 
Post-hoc analysis with Bonferroni correction further reveals that thapsigargin impairs cell viability in a dose-de-
pendent fashion; it triggers an approximately 7%, 20% (p ≤ 0.001) and 50% (p ≤ 0.001) decline in the number 
of viable, metabolically active cells that were accordingly challenged with 10, 100 and 1000 nM of the stressor, 
with respect to control conditions [Subigure 1(a)]. A dose-dependent cell growth arrest and membrane per-
turbation accompanies the suppressed cell viability. Specifically, the percentage of proliferating cells approxi-
mately decreases by 30% (p ≤ 0.001), 50% (p ≤ 0.001) and 60% (p ≤ 0.001) in microcultures exposed to 10, 100 
and 1000 nM of thapsigargin, respectively, when compared to control conditions [Fig. 1(b)]. Conversely, LDH 
release progressively increases by 8%, 30% (p ≤ 0.001) and 120% (p ≤ 0.001) in the supernatant of microcultures 
received the aforementioned stressor doses [Fig. 1(c)]. Two-way ANOVA analysis demonstrates that Liraglutide 
co-treatment significantly rescues abnormal LDH activity (F(3,436) = 16.91, p ≤ 0.001) and ameliorates cell viabil-
ity (F(3,442) = 8.14, p ≤ 0.001) and proliferation (F(3,355) = 11.75, p ≤ 0.001) impairments following chronic SERCA 
inhibition [Fig. 1]. Interestingly, Liraglutide approximately induces a 25% and 35% rise in the number of meta-
bolically active and proliferating cells when stressed with 100 nM of thapsigargin, and renders them indifferent 
from the control conditions [Fig. 1(a), (b)]. Similarly, Liraglutide co-treatment normalises the abnormal LDH 
activity in the SH-SY5Y microcultures received 100 nM of thapsigargin [Fig. 1(c)]. Therefore, we consider 100 nM 
of thapsigargin stress for further studies where Liraglutide fully restores cell physiology.
Liraglutide resolves UPR and brings homeostasis in the protein folding machinery of ER. Next, 
we investigated whether Liraglutide could regulate the UPR to promote neuroprotection in SH-SY5Y cells. Cells 
were treated with 0 and 100 nM of thapsigargin in the presence or absence of 100 nM Liraglutide for 16 h, and 
processed for immunoblotting analysis of hallmark ER stress-related signalling molecules. One-way ANOVA 
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analysis demonstrates overall significant differences in the binding immunoglobulin protein (BiP) (F(3,28) = 27.90, 
p ≤ 0.001), full-length ATF6 (F(3,28) = 6.267, p ≤ 0.01), IRE1α activation (F(3,27) = 8.683, p ≤ 0.001), CHOP 
(F(3,28) = 20.66, p ≤ 0.001), and active caspase 12 (CASP12) (F(3,28) = 4.185, p ≤ 0.05). In particular, chronic thapsi-
gargin treatment triggers a 1.5-fold increase in BiP expression [Fig. 2(a)] that indicates ER stress29, and a signifi-
cant increase in the full-length ATF6 levels (p ≤ 0.01), as shown in Fig. 2(c). Upon ER stress, ATF6 translocates to 
Golgi; there, it undergoes proteolytic cleavage at a juxtamembrane site to generate an active cytosolic ATF6 frag-
ment that subsequently migrates into the nucleus7. Although we could not consistently detect the active, 50- ATF6 
proteolytic fragment among the four immunoblotting experiments analysed (data not shown), confocal imaging 
has revealed a nuclear accumulation of this factor following chronic thapsigargin treatment in SH-SY5Y cells 
[Fig. 2(d)] that signifies ATF6 activation. Furthermore, chronic thapsigargin treatment significantly precludes 
the activating phosphorylation of IRE1α at the serine 724 residue (Ser724) (p ≤ 0.001), as compared to control 
conditions [Fig. 2(b)]. It additionally potentiates a 10-fold increase in CHOP (p ≤ 0.001) and almost doubles 
the active CASP12 fragment at 42 kDa (p ≤ 0.05), as shown in Fig. 3(a)–(b). Intriguingly, Liraglutide normalises 
abnormal BiP [Fig. 2(a)] and ATF6 [Fig. 2(c)] protein expression, and rescues IRE1α [Fig. 2(b)] and ATF6 activa-
tion [Fig. 2(d)]. Moreover, Liraglutide restores CASP12 up-regulation [Fig. 3(b)] and significantly ameliorates the 
ectopic CHOP expression by halving protein levels of this transcription factor (p ≤ 0.01), though they remained 
significantly elevated when compared to control conditions (p ≤ 0.01) [Fig. 3(a)].
To correlate the restorative effects of Liraglutide on the UPR with the ER proteostasis, we evaluated the pro-
tein expression of major protein quality-control chaperones, i.e., the ER oxidoreductase 1α (Ero1-Lα) [Fig. 3(c)], 
protein disulphide isomerase (PDI) [Fig. 3(d)] and calnexin [Fig. 3(e)]. One-way ANOVA analysis reveals overall 
significant differences in Ero1-Lα (F(3,28) = 3.668, p ≤ 0.05) and calnexin (F(3,28) = 11.62, p ≤ 0.001) but not in PDI 
expression (F(3,28) = 1.053, p = 0.3846). Post-hoc analysis shows that chronic thapsigargin treatment significantly 
up-regulates Ero1-Lα protein levels (p ≤ 0.05) whilst down-regulates calnexin by approximately 60% (p ≤ 0.001). 
Notably, Liraglutide co-treatment normalises abnormal protein expression of Ero1-Lα and calnexin, as shown in 
Fig. 3(c) and (e), respectively.
Figure 1. Liraglutide restores abnormal cytotoxicity and ameliorates impaired viability and proliferation in 
the neuroblastoma SH-SY5Y cell line upon persistent ER stress. Twenty-four hours post seeding, SH-SY5Y 
cells serum starved for 8 h and treated with 0, 10, 100 and 1000 nM of thapsigargin for 16 h, in the presence or 
absence of 100 nM Liraglutide. Cells were then assayed for XTT metabolisation [(a)] and BrdU incorporation 
[(b)] to assess cell viability and proliferation, respectively. Cell supernatant was collected and processed for LDH 
activity [(c)] to determine cytotoxicity. Each bar represents mean ± SEM from four independent experiments. 
All cell treatments were performed in sextuplicate per plate per experiment. Data is expressed as a percentage 
of the control (CNTRL; unstressed/untreated conditions). Data was analysed by one- and two-way ANOVA, 
followed by post hoc Bonferroni’s multiple comparison t-test (*p ≤ 0.05 & ***p ≤ 0.001 compared to CNTRL; 
##p ≤ 0.01 & ###p ≤ 0.001 compared to the corresponding thapsigargin-treated cells).
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Liraglutide rescues thapsigargin-induced autophagy impairments. ER-localised blocking of cal-
cium flux has been previously shown to perturb autophagosome biogenesis30 and fusion with lysosome31, culmi-
nating into autophagy arrest31,30 that can, in turn, elicit or enhance ER stress32. In this light, we investigated the 
expression of a set of autophagy-related (Atg) proteins following chronic thapsigargin and Liraglutide treatment 
[Fig. 4]. Protein expression of beclin (F(3,28) = 10.02, p ≤ 0.001), Atg3 (F(3,28) = 4.78, p ≤ 0.01), Atg7 (F(3,28) = 5.977, 
p ≤ 0.01) and of LC3 (F(3,28) = 6.557, p ≤ 0.01) significantly differs among groups, as evident by one-way ANOVA 
analysis. Post-hoc analysis demonstrates that chronic thapsigargin treatment significantly suppresses beclin 
(p ≤ 0.001) [Fig. 4(a)], Atg3 (p ≤ 0.01) [Fig. 4(b)], Atg7 (p ≤ 0.001) [Fig. 4(c)], and LC3 (p ≤ 0.001) [Fig. 4(d)] 
protein expression. Two-way ANOVA analysis indicates that Liraglutide co-treatment significantly alleviates 
impairments in beclin (F(1,28) = 23.07, p ≤ 0.001), Atg3 (F(1,28) = 12.52, p ≤ 0.01) and LC3 (F(1,28) = 7.43, p ≤ 0.05). 
Additionally, there is a trend of improvement by Liraglutide on the decreased Atg7 expression following thapsi-
gargin treatment (F(1,28) = 4.59, p ≤ 0.05), though it does not reach statistical significance when compared to the 
corresponding stress conditions in post-hoc analysis [Fig. 4(c)].
Liraglutide normalises aberrant nuclear accumulation of Nrf2 following ER stress and autophagy 
impairments. To further link aberrant UPR and autophagic machinery dysfunction to the antioxidant response 
in SH-SY5Y, we performed immunocytochemical analysis of the nuclear levels of the transcription factor Nrf2. 
Under basal conditions, Nrf2 is mainly localised to cytoplasm in a complex with the Kelch-like ECH-associated 
protein 1 (Keap1), an ubiquitin ligase substrate adaptor that targets Nrf2 for degradation33. Indeed, unstressed 
SH-SY5Y cells display a faint Nrf2-positive immunostaining that mainly resides in the peri-nuclear area [Fig. 5(a)]. 
However, in response to cellular stress, Nf2 dissociates from Keap1 and rapidly translocates into nucleus to confer 
its transcriptional activity33. Accordingly, we show that chronic thapsigargin treatment induces an aberrant nuclear 
accumulation of Nrf2 (post hoc; p ≤ 0.05) that is normalised by Liraglutide co-treatment [Fig. 5].
Figure 2. Liraglutide resolves UPR in the neuroblastoma SH-SY5Y cell line. Twenty-four hours post seeding, 
SH-SY5Y cells were serum starved for 8 h and treated with 0 or 100 nM of thapsigargin (TG) for 16 h, in the 
presence or absence of 100 nM Liraglutide (LIRA). Cells were harvested, and the expression of BiP [(a)] and 
ATF6 [(c)], as well the protein levels of total and phosphorylated IRE1α [(b)] were determined by western 
blotting. β-Actin was used as the loading control to all western blot analyses. Each bar represents mean ± SEM 
from four independent experiments. Data is expressed as fold change to the control (CNTRL; unstressed/
untreated conditions). Data was analysed by one- and two-way ANOVA, followed by post hoc Bonferroni’s 
multiple comparison t-test (**p ≤ 0.01 & ***p ≤ 0.001 compared to CNTRL; #p ≤ 0.05, ##p ≤ 0.01 & ###p ≤ 0.001 
compared to the corresponding thapsigargin-treated cells). [(d)] Representative pictures of SHSY5Y cells 
immunolabelled for ATF6 post thapsigargin and liraglutide treatments. Scale bars: 50 μm.
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Figure 3. Liraglutide ameliorates the ectopic expression of pro-apoptotic UPR mediators and promotes ER 
proteostasis in the neuroblastoma SH-SY5Y cell line upon persistent ER stress. Twenty-four hours post seeding, 
SH-SY5Y cells were serum starved for 8 h and treated with 0 or 100 nM of thapsigargin for 16 h, in the presence 
or absence of 100 nM Liraglutide. Cells were harvested, and the expression of CHOP [(a)], caspase 12 (CASP12) 
[(b)], ER oxidoreductase 1 alpha (Ero1-Lα) [(c)], protein disulfide isomerase [PDI; (d)] and of calnexin [(e)] 
were determined by western blotting. β-Actin was used as the loading control to all western blot analyses. Each 
bar represents mean ± SEM from four independent experiments. Data is expressed as fold change to the control 
(CNTRL; unstressed/untreated conditions). Data was analysed by one- and two-way ANOVA, followed by post 
hoc Bonferroni’s multiple comparison t-test (*p ≤ 0.05, **p ≤ 0.01 & ***p ≤ 0.001 compared to CNTRL; #p ≤ 0.05, 
##p ≤ 0.01 & ###p ≤ 0.001 compared to the corresponding thapsigargin-treated cells).
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Liraglutide restores impaired STAT3 activity and activates Akt signalling to ameliorate 
thapsigargin-induced apoptosis. Our findings motivated us to scan for the signalling network that underlies 
the cross-talk among the different sub-cellular compartments and mediates the neuroprotective/restorative effects 
of Liraglutide [Figs 6 and 7, Table S1]. Sandwich-based antibody array has revealed that persistent disturbance of 
ER calcium homeostasis significantly precludes the activating phosphorylation of the extracellular signal-regulated 
kinase 1/2 (ERK1/2) at threonine 202 (Thr202) and tyrosine 204 (Tyr204) residues (p ≤ 0.05) and of Stat3 at Tyr705 
(p ≤ 0.01), as shown in Fig. 6(b),(f), respectively. It additionally induces the glycogen synthase kinase 3β (GSK3β) 
[Fig. 6(d)] by halving the inhibitory phosphorylation of the kinase at the serine 9 (Ser9) residue (p ≤ 0.001), and 
significantly impedes the phosphorylation of the stress-responsive p53 at Ser15 (p ≤ 0.05) [Fig. 6(e)]. All these alter-
ations in the signalling molecules further correlate to a two-fold increase (p ≤ 0.001) in cleaved poly (ADP-ribose) 
polymerase (PARP) [Fig. 6(h)] that assures the fulfilment and irreversibility of the apoptotic process34 upon a 16- 
time course of thapsigargin treatment in SH-SY5Y cells. Liraglutide rescues STAT3 activation (p ≤ 0.05) [Fig. 6(f)] 
but does not alleviate ERK1/2 impairments [Fig. 6(b)]. Moreover, Liraglutide restores GSK3β [Fig. 6(d)] and p53 
[Fig. 6(e)] activity to the baseline levels, and significantly provokes Akt phosphorylation at Thr308 (p ≤ 0.05) under 
chronic thapsigargin treatment in the SH-SY5Y cells [Fig. 6(c)]. Liraglutide significantly attenuates ectopic PARP 
proteolysis (p ≤ 0.05) upon unmitigated UPR and autophagy impairments that signifies cytoprotection, though it 
remained significantly elevated when compared to control conditions (p ≤ 0.05) in post-hoc analysis [Fig. 6(h)].
It is well documented that the majority of pro-death signals emerging from UPR regulate the expression and 
activity of pro- and anti-apoptotic proteins of BCL-2 family6,8. Consistently, we report that persistent ER-localised 
blocking of calcium flux diminishes the inhibitory phosphorylation of the pro-apoptotic BAD at Ser112 (p ≤ 0.05) 
[Fig. 6(g)], accompanied by a significant de-phosphorylation of the survival-agonist Bcl-2 at Ser70 (p ≤ 0.01) 
[Fig. 7(a)]. Liraglutide normalises aberrant BAD [Fig. 6(g)] and Bcl-2 [Fig. 7(a)] phosphorylation patterns and fur-
ther down-regulates the normal expression of the full-length BH3 interacting-domain death agonist (BID) [Fig. 7(b)].
Figure 4. Chronic disturbance of ER calcium homeostasis diminishes “core” Atg proteins required for 
autophagosome formation. Liraglutide rescues autophagy impairments in the neuroblastoma SH-SY5Y cell 
line upon persistent ER stress. Twenty-four hours post seeding, SH-SY5Y cells were serum starved for 8 h 
and treated with 0 or 100 nM of thapsigargin for 16 h, in the presence or absence of 100 nM Liraglutide. Cells 
were harvested, and the expression of beclin [(a)], ATG3 [(b)], ATG7 [(c)] and of LC3 [(d)] were determined 
by western blotting. β-Actin was used as the loading control to all western blot analyses. Each bar represents 
mean ± SEM from four independent experiments. Data is expressed as fold change to the control (CNTRL; 
unstressed/untreated conditions). Data was analysed by one- and two-way ANOVA, followed by post hoc 
Bonferroni’s multiple comparison t-test (**p ≤ 0.01 & ***p ≤ 0.001 compared to CNTRL; #p ≤ 0.05, ##p ≤ 0.01 & 
###p ≤ 0.001 compared to the corresponding thapsigargin-treated cells).
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Discussion
Neuronal injury owing to chronic and irremediable ER stress has been increasingly correlated with a range of neu-
rodegenerative disorders while UPR activation and deregulation has been repeatedly found in postmortem brain 
samples from affected patients and animals of AD, PD, ALS, HD, and experimental stroke1–5. Pharmacological 
and genetic manipulation approaches have unravelled promising mechanisms that link ER stress to neurode-
generative processes. In particular, AD features the accumulation of amyloid-β (A β) peptides in the brain, 
which underlies neuronal dysfunction and cognitive decline. Aβ primarily perturbs the cellular redox status and 
abnormally increases the amount of calcium that can be released by the ER, triggering ER stress, mitochondrial 
dysfunction and thereby neuronal toxicity and astrogliosis in vivo1,4. Accordingly, α-Synuclein, the molecular 
determinant of PD pathobiology, alters the interactions between ER and mitochondria, which triggers an aber-
rant increase in the mitochondrial calcium content and compromises mitochondrial membrane potential, auto-
phagic function and cellular bioenergetics35. Recent studies have further revealed that α-synuclein preferentially 
accumulates within the ER\microsomes, where it aggregates in toxic oligomeric formations in mouse and human 
brain with α–synucleinopathy. Those oligomeric forms have been further associated with the onset of chronic ER 
stress and disease progression36,37. UPR and ER calcium dynamics seem to additionally govern neuronal injury 
progression in HD38,39, TBI and following stroke3. Therefore, resolution of chronic ER stress can benefit acute 
and chronic neurodegenerative disorders that feature diverse aetiologies and clinical manifestations3–5, whilst 
Figure 5. Autopphagy impairments along with UPR deregulation up-regulate the nuclear content of the 
nuclear factor erythroid 2-related factor 2 (Nrf2). Liraglutide restores Nrf2 signalling in the neuroblastoma 
SH-SY5Y cell line upon irremediable ER stress. Twenty-four hours post seeding, SH-SY5Y cells were serum 
starved for 8 h and treated with 0 or 100 nM of thapsigargin (TG) for 16 h, in the presence or absence of 
100 nM Liraglutide (LIRA). Cells were paraformaldehyde-fixed, immunolabelled for Nrf2 and processed 
for confocal imaging at 40X magnification, as shown in the representative images [(a)]. Eight pictures were 
captured per experimental group per experiment for quantification. Image J was used to quantify corrected 
total cell fluorescence (CTCF) of the nuclear Nrf2 staining [(b)]. Each bar represents mean ± SEM from three 
independent experiments. Data was analysed by one- and two-way ANOVA, followed by post hoc Bonferroni’s 
multiple comparison t-test (*p ≤ 0.05 compared to CNTRL; #p ≤ 0.05 compared to the corresponding 
thapsigargin-treated cells). Scale bars: 50 μm.
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Figure 6. Chronic disturbance of ER calcium homeostasis induces PARP cleavage, diminishes inhibitory 
phosphorylation of the pro-apoptotic BAD protein and of the multifunctional GSK3b kinase, and impairs ERK 
and STAT3 signalling to promote genotoxicity and apoptosis. Liraglutide rescues PARP cleavage and activation 
of STAT3 and p53 kinases. It additionally induces Akt phosphorylation that relieves BAD and GSK3b activity 
to promote cell survival in the neuroblastoma SH-SY5Y cell line upon persistent ER stress. Twenty-four hours 
post seeding, SH-SY5Y cells were serum starved for 8 h and treated with 0 or 100 nM of thapsigargin for 16 h, in 
the presence or absence of 100 nM Liraglutide. Cells were harvested, and Bcl-2 phosphorylation [(a)] and BID 
expression [(b)] were determined by western blotting. β-Actin was used as the loading control to all western 
blot analyses. Each bar represents mean ± SEM from four independent experiments. Data is expressed as fold 
change to the control (CNTRL; unstressed/untreated conditions). Data was analysed by one- and two-way 
ANOVA, followed by post hoc Bonferroni’s multiple comparison t-test (*p ≤ 0.05, **p ≤ 0.01 & ***p ≤ 0.001 
compared to CNTRL; #p ≤ 0.05 & ##p ≤ 0.01 compared to the corresponding thapsigargin-treated cells).
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prolonged perturbation of ER calcium homeostasis may offer an integrated cellular model to simulate neurode-
generative processes for drug discovery.
GLP-1 analogues, which are currently approved for T2DM treatment, have been repeatedly shown to 
exert neurotrophic/restorative effects in a range of animal models of AD, PD, ALS, TBI and experimental 
stroke11–18,40–48. Importantly, GLP-1 mimetics, such as Liraglutide has rescued the AD-related reduction in cortical 
activity and energy utilisation22, and a recently phase II clinical trial testing Exenatide has impeded PD progres-
sion25. The underlying biochemical processes are manifold. Incretin mimetics have prevented aberrant apoptosis 
of (hippocampal and primary cortical and dopaminergic) neurons and SH-SY5Y neuroblastoma cells exposed to 
hypoxia, excitotoxic insults, neurotoxins (e.g., hydrogen peroxide and oxidopamine) and thapsigargin-induced 
ER stress17,18,49,50. Liraglutide pre-treatment favours cell survival over apoptotic signalling to promote cytopro-
tection from persistent mitochondria dysfunction in SH-SY5Y cells21. Similarly, post-treatment with GLP-1R 
agonists rescues aberrant cytotoxicity and impaired viability, and further enhances cell survival signalling to 
protect SH-SY5Y neuroblastoma cells from chronic rotenone-induces oxidative stress19. In the present study, we 
have addressed the neuroprotective/restorative effects of Liraglutide, along with the underlying molecular mech-
anisms and signalling network after prolong perturbation of ER calcium homeostasis. Consistently, we report 
that Liraglutide impedes the increase in the number of SH-SY5Y cells with compromised plasma membrane and 
mitochondrial dysfunction induced by thapsigargin, and promotes cell proliferation in a stressor dose-dependent 
manner.
Thapsigargin is a specific, almost irreversible inhibitor of the SERCA channel, triggering a transient increase 
in the cytosolic calcium and depleting ER calcium stores28. Calcium depletion in the ER precludes the activity of 
calcium-dependent chaperones to potentiate the accumulation of unfolded/misfolded proteins within the orga-
nelle lumen and thereby ER stress7. In response, the cell activates the UPR network that integrates signals about 
the chronicity and severity of the stress stimuli and culminates into disproportionate activation of PERK, ATF6 
and IRE1α signalling to determine cell fate6,8,51. Particularly, chronic ER stress augments PERK arm to amplify 
the transcription and translation of the pro-apoptotic transcription factor CHOP51, whilst it suppresses IRE1α 
signalling51,52 to possibly attenuate the survival and neurotrophic effects of the downstream spliced X-box bind-
ing protein 1(XBP-1) and sensitise the cells to ER stress8. It can additionally enhance ATF6 activity to reinforce 
CHOP expression and thus amplify the apoptotic component of the UPR8,51. Consistently, we have demonstrated 
that chronic thapsigargin treatment up-regulates ATF6 which accumulates in the cell nuclei and signifies its 
activation, whilst almost abolishes the activating phosphorylation of IRE1α at Ser724. We additionally show that 
chronic thapsigargin treatment triggers an ectopic expression of CHOP that correlates with calnexin deficiency 
and ERO1α excess in SH-SY5Y neuroblastoma cells. Calnexin silencing has been previously reported to sensitise 
cardiomyocytes to ER stress and favour apoptosis through CHOP up-regulation and calcium deregulation53. 
Furthermore, induction of the oxidoreductase ERO1α downstream of CHOP perturbs the ER redox state54 that 
in turn stimulates inositol-1,4,5-trisphosphate receptor (IP3R)-mediated calcium efflux into cytosol55. The latter 
could influence multiple pathways upstream of the core apoptosis machinery and, most importantly, mitochon-
drial function56,57. In addition to CHOP, persistent ER stress can activate the ER-resident CASP12 to further 
Figure 7. Chronic disturbance of ER calcium homeostasis diminishes Bcl-2 phosphorylation at serine 70 
to promote cell apoptosis, though it does not affect the expression levels of the pro-apoptotic BID protein. 
Liraglutide restores Bcl-2 activation and further promotes a decrease in BID protein levels in the neuroblastoma 
SH-SY5Y cell line upon persistent ER stress. Twenty-four hours post seeding, SH-SY5Y cells were serum 
starved for 8 h and treated with 0 or 100 nM of thapsigargin for 16 h, in the presence or absence of 100 nM 
Liraglutide. Cells were harvested, and Bcl-2 phosphorylation [(a)] and BID expression [(b)] were determined 
by western blotting. b-Actin was used as the loading control to all western blot analyses. Each bar represents 
mean ± SEM from four independent experiments. Data is expressed as fold change to the control (CNTRL; 
unstressed/untreated conditions). Data was analysed by one- and two-way ANOVA, followed by post hoc 
Bonferroni’s multiple comparison t-test (**p ≤ 0.01 compared to CNTRL; #p ≤ 0.05 & ##p ≤ 0.01 compared to the 
corresponding thapsigargin-treated cells).
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promote cell suicide. CASP12 provokes a downstream caspase cascade that leads to PARP degradation and there-
fore programmed cell death initiation58–60, as reflected in our results too. Intriguingly, Liraglutide co-treatment 
normalises BiP induction along with ATF6 and IRE1α signalling in thapsigargin-treated SH-SY5Y cells. It addi-
tionally mitigates abnormal CHOP expression and CASP12 activity, restores calnexin and ERO1α expression, 
and alleviates PARP degradation. These biochemical traits further relate to the restoration of SH-SY5Y cell via-
bility and proliferation. Collectively, our findings suggest that GLP-1R activation resolves the induction of UPR 
effectors and pro-apoptotic mediators and promotes chaperone homeostasis in the ER lumen, which signifies cell 
proteostasis upon persistent, neuronal ER stress.
Acute SERCA channel inhibition has been shown to preclude autophagosome formation30 and fusion with 
lysosomes31, resulting into autophagy arrest30,31. Autophagy fail along with deregulated UPR seem to drive the 
imbalance between protein generation and degradation that underlies the onset and progression of neuronal 
degeneration1,5,32. Autophagy is a tightly regulated pathway that allows cells to eliminate harmful or damaged 
components through catabolism and recycling to maintain nutrient and energy homeostasis. As such, autophagy 
constitutes a crucial mechanism for preserving structures and functioning of subcellular organelles, including 
ER and mitochondria, when operates at basal levels, and for cell survival in response to stress1,5,32. Several stud-
ies have shown that Liraglutide promotes autophagy and thereby cell survival in liver, pancreas and SH-SY5Y 
cells19,61–66. Contrarily, Zhao et al. have demonstrated a cytoprotective effect of Liraglutide by inhibiting auto-
phagy in renal tubular epithelial cells67. Similarly, Liraglutide has prevented oxidative stress-induced axonal injury 
by halting excessive autophagy in retinal ganglion cells68. Excessive autophagic flux can exert detrimental effects 
by aberrantly degrading endogenous inhibitors of apoptosis and Atg components, and lead to cell death. That 
dual role has been further attributed to autophagy under ER stress conditions32. Here, we show that apoptotic 
ER stress correlates with a substantial decrease in the protein levels of beclin-1, which determines the initiation 
and formation of phagophore. Suppressed IRE1α and Bcl-2 phosphorylation may underlie beclin-1 impairments 
following prolonged thapsigargin-treatment in SH-SY5Y cells. Previous studies have revealed that, among the 
three UPR arms, the induction of pro-survival autophagy after ER stress requires IRE1 signalling69. The latter 
mediates the phosphorylation of Bcl-2, which results in its dissociation from and to the release of beclin-170. In 
addition, spliced XBP1, lying downstream of IRE1 arm, has been previously shown to bound to the promoter 
of beclin-1 and induce its transcription71. Furthermore, we demonstrate that chronic ER calcium dyshomeosta-
sis culminates into Atg3, Atg7 and LC3 protein deficiency that may result from the ectopic CHOP expression. 
Indeed, CHOP has been previously shown to limit autophagy through the transcriptional control of a dozen of 
Atg genes involved in phagophore elongation and maturation into the autophagosome, and thereby to stimu-
late apoptosis upon persistent ER stress72,73. Autophagy dysfunction along with persistent ER stress can further 
trigger the excess accumulation of the autophagy adaptor protein p6274, which contains a KEAP1 binding motif 
similar to Nrf275. Accumulation of p62 leads to KEAP1 sequestration and inactivation, which, in turn, promotes 
aberrant nuclear Nrf2 localisation and transcription of Nrf2 target genes75. Although the Nrf2 transcription pro-
gram has been recognised as one of the main antioxidant defensive mechanisms for cytoprotection33, that con-
stitutive Nrf2 activation along with autophagy preclusion has been previously shown to drive the hepatic injury 
observed in Atg7-knockout mice75. Accordingly, we report that the deficiency in the “core” Atg components, lying 
downstream of prolong ER calcium perturbation, correlates with Nrf2 hyperactivaiton, suggesting that regulated 
Nrf2 activation can benefit cellular defensive responses to stress. Strikingly, Liraglutide co-treatment ameliorates 
Atg3, Atg7, beclin-1, and LC3 expression impairments and further normalises aberrant Nrf2 and Bcl-2 activity 
in thapsigargin-treated SH-SY5Y cells. Taken together, our findings highlight that GLP-1R activation promotes 
ER and autophagic machinery homeostasis that signifies about cell adaptation and survival upon unmitigated, 
neuronal ER stress.
Mechanistically, Liraglutide restores impaired STAT3 signalling and engages Akt pathway to exert its neu-
roprotective/restorative effects upon persistent ER stress. STAT3 is a latent transcription factor that is primarily 
activated by the phosphorylation of a single tyrosine residue, Tyr705, in response to the stimulation of cytokine 
and growth factor receptors76,77, including GLP-1R78. Once activated, STAT3 dimerises and enters the nucleus to 
orchestrate – alone or in cooperation with other factors – transcriptional programs for neuronal/glial survival, 
proliferation and differentiation76. Suppressed STAT3 activity has been previously found in the hippocampus of 
postmortem brain samples from AD patients and transgenic mice79. Chiba et al. have further demonstrated that 
Aβ inactivates hippocampal JAK2 (Janus kinase 2)/STAT3 axis to provoke the basal forebrain cholinergic dys-
function and spatial working memory deficits in vivo, linking STAT3 pathway to neurodegenerative processes79. It 
has been additionally recognised that ER stress perturbs JAK-signal transducers and STAT3 signalling to mediate 
acute-phase neuroinflammatory responses80 and leptin resistance in the brain81 or to drive apoptosis that under-
lies suppressed hepatic gluconeogenesis82 in periphery. Although the mechanistic interplay among UPR, STAT3 
signalling and GLP-1R in the context of cell fate and neuronal degeneration remains unknown, STAT3 has been 
recently emerged as a multifaceted determinant for autophagy77. For instance, nuclear STAT3 can transcription-
ally induce the anti-apoptotic Bcl-2 expression and consequently inhibit autophagy83. However, this phenotype 
is not prominent on our findings as no changes in total Bcl-2 levels occur following chronic thapsigargin and/
or Liraglutide treatments in SH-SY5Y cells [Figure S1]. Intriguingly, Atg3 promoter has been recently shown 
to contain a STAT3-responsive element84, which may explain the restorative effects of Liraglutide against the 
thapsigargin-induced Atg3 deficiency, though this hypothesis requires further investigation.
Akt (also known as protein kinase B – PKB) is a serine/threonine kinase member of the AGC protein kinase 
family with a profound function in growth, proliferation, intermediate metabolism and cell survival85, and a 
pivotal effector of the anti-apoptotic GLP-1R signalling21. In response to the phosphoinositide 3-kinase (PI3K) 
stimulation, Akt is recruited to the cell membrane86 where it can undergo phosphorylation at the threonine 308 
(Thr308) residue by PDK187 and at the serine 473 (Ser473) residue by mTORC288. Phosphorylation of Thr308 
site critically determines Akt activation whilst phosphorylation of both aforementioned sites is required for the 
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maximal kinase activity86,89. In our study, Liraglutide has significantly increased the phosphorylating levels of 
Akt at Thr308 that signifies kinase activation. Activated Akt phosphorylates multiple targets in the cytoplasm, 
nucleus, mitochondria and ER membrane to regulate adaptive responses and cell fate under diverse insults, 
including ER and oxidative stress and DNA damage85,89–91. Among others, Akt phosphorylates and inhibits the 
death-agonist BAD that becomes rapidly de-phosphorylated upon apoptotic stimuli89, as prominent in our find-
ings too. Active (de-phosphorylated) BAD binds to the survival-agonist Bcl-xL or Bcl-2 at the mitochondria that 
provokes Bax and Bak oligomerisation and perturbs mitochondrial membrane permeabilisation to favour the 
point-of-no-return of apoptotic cell death92–94. However, the restoration of BAD phosphorylation downstream of 
growth factor signalling raises the mitochondrial threshold for apoptosis that renders the cells less vulnerable to 
death signals95, as evident in our results too.
In addition to BAD, Akt phosphorylates and inhibits the GSK3β, a major protein kinase that drives neu-
rodegenerative processes in AD96 and neuronal apoptosis following ER stress97–100. Indeed, accumulating evi-
dence from diverse neuronal cell lines, primary neuronal cultures, and ER insults has demonstrated that the UPR 
abolishes the inhibitory phosphorylation of GSK3β at Ser997–100 to promote CHOP expression and switch from 
pro-survival to pro-death signalling during ER stress98, as reflected in our results too. Moreover, it has been pre-
viously reported that PERK engages GSK3β to phosphorylate the p53 tumour suppressor protein at Ser315 and 
Ser376 and favour nuclear export and proteosomal degradation of p53 upon ER stress101,102. p53 is transcription 
factor of which activation serves to organise cellular responses with apoptosis, cell cycle arrest, senescence, DNA 
repair, cell metabolism, or autophagy depending on the nature and degree of stress insult, environmental context, 
and cell type. The regulation of p53 is complex and involves post-translational modifications – e.g., phosphoryla-
tion and acetylation – at multiple sites that impact its cellular localisation, stability and transcriptional activity103. 
We assessed the phosphorylated levels of p53 at Ser15 that facilitates p53 nuclear accumulation and stabilisation 
by halting the ability of the E3 ubiquitin-protein ligase Mdm2 to interact with and target p53 for proteosomal 
degradation104,105. Our findings indicate that chronic ER stress precludes the phosphorylation of p53 at Ser15 
and further confirm that ER stress leads to p53 destabilisation101,102, though different phosphorylation sites were 
examined among the studies. In our study, the p53 destabilisation seems to lie downstream of the decreased 
activity of ERK1/2, which has been previously shown to regulate the phosphorylation of this transcription factor 
at Ser15 in SH-SY5Y cells106. Although Liraglutide does not alleviate the impaired ERK1/2 phosphorylation, it 
potentiates Akt signalling which has been previously shown to potentiate the atypical p53-related protein kinase 
and phosphorylate p53 at Ser15 in human cell lines107, as well as to restore p53 stabilisation following cellular 
stress108. Intriguingly, it has been recently reported that Akt phosphorylates and inhibits PERK109, which may 
offer an additional mechanistic link on how Liraglutide confers its restorative effects on p53, though necessitates 
further experimentation.
Though not examined in the present study, Liraglutide may restore calcium homeostasis to elicit neuroprotec-
tion upon chronic thapsigargin treatment. Previous studies have demonstrated that GLP-1R induction potentiates 
cyclic AMP (cAMP) production20 and regulates calcium responses21,49, which underlie protection of hippocam-
pal neurons and SH-SY5Y neuroblastoma cells from excitotoxicity49 and oxidative stress-induced21 apoptosis, 
respectively. Furthermore, cAMP increase by GLP-1R stimulation potentiates protein kinase A (PKA) that 
downstream induces SERCA function to promote cytoprotection in insulin-resistant macrophages110 and high 
glucose-treated cardiomyocytes111. Accordingly, PKA pharmacological inhibition blocks the GLP-1R-mediated 
anti-apoptotic effects, whilst the adenylate cyclase activator, Forskolin mimics the GLP-1R-induced cardioprotec-
tion upon hyperglycaemia111. cAMP has been additionally shown to potentiate cAMP-regulated guanine nucleo-
tide exchange factors (also known as Epac) that regulate calcium dynamics in response to GLP-1R stimulation112.
In conclusion, our study demonstrates the neuroprotective/restorative effects of Liraglutide upon unmitigated 
neuronal ER stress. It further unravels a complex signalling network through which Liraglutide regulates UPR 
outcome, elicits autophagy machinery homeostasis and shifts cell fate from apoptosis to survival, providing addi-
tional evidence for the beneficial effects of GLP-1R stimulation and signalling in neurodegenerative disorders and 
deepening our understanding of the underlying mechanism.
Materials and Methods
Materials. Cell proliferation kit II [2,3-Bis-(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-
carboxanilide (XTT)], cell proliferation ELISA 5-bromo-2′-deoxyuridine (BrdU) kit and Cytotoxicity Detection 
KitPLUS [lactate dehydrogenase (LDH)] were purchased from Roche Diagnostics Ltd (West Sussex, UK). The ER 
Stress Antibody Sampler Kit (#9956), beclin-1 (D40C5) monoclonal antibody (#3495), Atg3 monoclonal antibody 
(#3415), Atg7 monoclonal antibody (#8558), LC3B polyclonal antibody (#2775), Bcl-2 (D17C4) monoclonal anti-
body (#3498), phospho-Bcl-2 (Ser70) (5H2) monoclonal antibody (#2827), BID (Human Specific) polyclonal 
antibody (#2002), β-Actin (8H10D10) monoclonal antibody (#3700), PathScan® Intracellular Signaling Array 
Kit (#7323), PathScan® Sandwich ELISA Lysis Buffer (1X), Protease/Phosphatase Inhibitor Cocktail (100X), 
and horseradish peroxidase(HRP)-linked secondary antibodies against the corresponding species IgG of the 
primary antibodies (#7074 & #7076) were purchased from Cell Signaling Technology (New England Biolabs 
UK Ltd, Hertfordshire, UK). Phospho-IRE1 (S724) polyclonal antibody (ab48187), ATF6 [1-7] polyclonal anti-
body (ab122897), CASP12 polyclonal antibody (ab62484), Nrf2 [EP1808Y] (ab62352) monoclonal antibody and 
normal goat serum were purchased from Abcam (Cambridgeshire, UK). Quick Start™. Bradford protein assay 
kit was obtained from BIO-RAD Laboratories Ltd (Hertfordshire, UK). Amersham ECL Prime western blot-
ting detection reagent kit was obtained from GE Healthcare Life Sciences (Buckinghamshire, UK). Invitrogen® 
goat anti-rabbit IgG H & L Alexa Fluor® 488 secondary antibody (A11034), Invitrogen™ iBlot® 2 Dry Blotting 
System, iBlot™ 2 Transfer Stacks with integrated nitrocellulose transfer membranes, precast polyacrylamide 
Bolt™ 4–12% gradient Bis-Tris Plus gels, and Restore™ PLUS Western Blot Stripping Buffer were purchased 
from Fisher Scientific UK Ltd (Leicestershire, UK). Bovine serum albumin (BSA), tris buffered saline (TBS; pH 
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8.0) supplemented or not with 0.05% Tween® 20, phosphate buffered saline (PBS; pH 7.4), paraformaldehyde 
and dimethyl sulfoxide (DMSO; anhydrous, ≥ 99.9%) were obtained from Sigma-Aldrich Company Ltd (Dorset, 
UK). Other materials and reagents for cell culture, western blotting and immunocytochemistry were purchased 
from Fisher Scientific UK Ltd (Leicestershire, UK), unless otherwise stated. No ethical approval was required for 
the current work.
Cell culture. The human neuroblastoma SH-SY5Y cell line (ATCC® CRL2266™) was obtained from 
LGC Standards (Middlesex, UK) and cultivated in Dulbecco’s modified eagle medium/nutrient mixture F-12 
(DMEM/F-12, 1:1; 1X) Glutamax™ supplemented with 10% heat-inactivated foetal bovine serum (FBS), 
100 IU ml−1 of Penicillin and 100 μg ml−1 of Streptomycin. Cells were maintained at 37 °C in a humidified incu-
bator with 5% CO2 and 95% air. Cells were subcultured when 80–90% confluent and seeded at 1:10 ratio. When 
passaged, viable cells were counted and seeded at the desired cell density for the assays using the Countess™ 
Automated Cell Counter (Thermo Fisher Scientific, Inchinnan Business Park, Paisley, UK). The latter is based on 
the standard trypan blue exclusion technique, in which dead cells are selectively permeable to the dye and stained 
blue. Culture medium was renewed every 3 to 4 days.
Cell treatments. Thapsigargin was received as a colourless solid film, solubilised in 100% dimethyl sulfoxide 
(DMSO) at a concentration of 1 mM, aliquoted and stored at  −20 °C until used. For the experiments, thapsi-
gargin stock preparations were serially diluted in serum-free culture medium at final working concentrations 
of 10 to 1000 nM, containing ≤0.1% DMSO; DMSO (≤0.1%) did not affect cell viability and proliferation as 
assessed in preliminary experiments (data not shown).
Liraglutide was purchased from GL Biochem Ltd (Shanghai, China). The purity of the peptide was ana-
lysed by reverse-phase HPLC and characterised using matrix-assisted laser desorption ionisation time-of-flight 
(MALDI - TOF) mass spectrometry, as previously described113. The peptide was reconstituted in Gibco Water for 
Injection for Cell Culture to a concentration of 1, aliquoted and stored at −20 °C until used. For the experiments, 
Liraglutide stock preparations were diluted in serum-free culture medium to a final working concentration of 
100 nM. The concentration was selected on the basis of previous experiments in which our group has established 
optimal working concentrations for the neuroprotective and anti-apoptotic effects of Liraglutide19,21.
Cell viability, proliferation and cytotoxicity assessment. Cell viability, proliferation and cytotox-
icity were determined using Cell proliferation kit II (XTT), cell proliferation ELISA BrdU (colorimetric) kit 
and Cytotoxicity Detection KitPLUS (LDH), respectively. The assays were formatted in Nunc™ MicroWell™ 
flat-bottomed 96-well plates. SH-SY5Y cells were seeded at a density of 2 × 104 cells per well for 24 h. The cells 
were subsequently serum starved in serum-free medium for 8 h and stressed with different concentrations of 
thapsigargin for 16 h, in the presence or absence of 100 nM of Liraglutide. All cell treatments were performed in 
sextuplicate per plate per experiment. Following cell treatments, 50 μL of XTT labelling reagent and 1 μL of elec-
tron coupling reagent was added to each well, yielding final XTT concentration of 0.3 mg mL−1. Cells were incu-
bated with the XTT labelling mixture for 6 h at 37 °C in a humidified incubator with 5% CO2 and 95% air. Plates 
were then gently shaken for 5 min on a Microtitre plate shaker (Stuart, Staffordshire, UK) and absorbance was 
measured at 492 and 690 nm (reference wavelength) in a Infinite® 200 PRO microplate reader (Tecan, Berkshire, 
UK). The assay rests on the cleavage of the yellow tetrazolium salt XTT into an orange, water-soluble formazan 
product by metabolically active cells (mitochondrial dehydrogenase enzyme activity). Thus, absorbance values 
are proportional to the number of viable cells in the respective microcultures.
Alternatively, SH-SY5Y cells were incubated with 10 μM BrdU labelling solution for 6 h at 37 °C in a humid-
ified incubator with 5% CO2 and 95% air. The pyridine analogue BrdU was incorporated, in place of thymidine, 
into the newly synthesised DNA strands of proliferating cells. BrdU incorporation was detected by immunop-
eroxidase staining and a subsequent colorimetric substrate reaction as per manufacturer’s protocol. Plates were 
read at 450 and 690 nm (reference wavelength) using Infinite® 200 PRO microplate reader. Developed colour 
and absorbance values reflect the amount of DNA synthesis, and hereby the number of proliferating cells in the 
respective microcultures.
Cytotoxicity Detection KitPLUS was used to quantify LDH activity; LDH is a stable cytoplasmic enzyme present 
in all cells and rapidly released into the culture supernatant upon plasma membrane damage. The assay involves 
a coupled enzymatic reaction that results in the formation of a red, water-soluble formazan product during a 
limited time period. The amount of colour developed is proportional to the number of damaged/lysed cells in the 
respective microcultures. As per manufacturer’s instructions, following cell treatments, 50 μL of cell supernatant 
was collected and incubated with the provided reaction mixture for 30 min at room temperature. The reaction was 
terminated by adding the Stop Solution from the kit and absorbance was measured at 490 and 650 nm (reference 
wavelength).
Sample collection and protein extraction. 2×106 cells were grown at 75 cm2 Nunc™ Cell Culture 
Treated EasYFlasks™ for 24 h. Following serum starvation for 8 h, cells were stressed with 100 nM of thapsigargin 
for 16 h, in the presence or absence of 100 nM of Liraglutide. Thereafter, cells were washed once with ice-cold 1X 
phosphate-buffered saline (PBS) and harvested in 1X cell lysis buffer containing protease/phosphatase inhibitor 
cocktail (1X). After two freeze/thaw cycles, whole-cell lysate was collected and total protein was extracted by cen-
trifugation at ~16000×g at 4 °C for 15 min. Quick start™ Bradford protein assay was conducted to estimate the 
protein concentration of the samples, as previously described19,21.
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Western blotting. Protein of whole-cell lysate (4 μg) was reduced and denaturated by boiling in lithium 
dodecyl sulfate (LDS) sample buffer containing 50 mM dithiothreitol (DTT) at 95 °C for 5 min. Replicate pro-
tein samples were separated on Bolt™ 4–12% gradient Bis-Tris gel and blotted onto nitrocellulose membranes 
using iBlot® 2 Dry Blotting System. Blots were washed once in 1X TBS for 5 min, blocked in 5% w/v skimmed 
milk for 1 h at room temperature, and probed with the primary antibodies against BiP, calnexin, Ero1α, PDI, 
IRE1α, CHOP, ATF6 (1:500), CASP12 (1:2000), BID, LC3, ATG3, ATG7, beclin, and β-actin (1:104) overnight at 
4 °C. Alternatively, blots were blocked in 5% BSA and probed with the primary antibodies against phospho-IRE1 
(Ser724) and phospho-Bcl-2 (Ser70) overnight at 4 °C. All the primary antibodies used were diluted in 5% BSA 
in 1X TBS with 0.05% Tween® 20 (TBS–T; pH 8) at 1:1000 ratio, unless otherwise specified. All the primary 
antibodies used were generated in rabbit, except for the antibodies against CHOP, ATF6 and β-actin which were 
raised in mice. Following primary antibody incubation, blots were washed three times in 1X TBS–T for 5 min 
each and incubated with the HRP-linked secondary antibodies against the corresponding species IgG (1:2000) for 
1 h at room temperature. Blots were developed using Amersham ECL Prime western blotting detection reagent 
kit as per manufacturer’s instructions. ChemiDoc™ MP Imaging System with Image Lab™ software (BIO-RAD 
Laboratories Ltd, Hertfordshire, UK) used to image chemiluminescent bands and perform densitometric analysis. 
β-Actin protein was served as loading control to which relative peak intensities of the examined markers were 
normalised. To reprobe, blots were incubated in Restore™ PLUS stripping buffer for 20 min at 37 °C with gentle 
agitation and subsequently washed three times in TBS for 5 min each. Chemiluminescent detection to ensure the 
removal of the original signal preceded blot re-incubation with another primary antibody of interest.
PathScan® sandwich immunoassay. The PathScan® Intracellular Signaling Array kit was used in 
accordance to manufacturer’s protocol. Briefly, 100 μL Array Blocking Buffer was added to each well of the 
the antibody array slide and incubated for 15 min at room temperature. Thereafter, protein of whole-cell lysate 
(0.3 mg mL−1) was placed onto each well and incubated overnight at 4 °C with gentle agitation. All samples per 
experiment were processed in duplicate. The following day, all the wells were washed three times in 1X Array 
Wash Buffer for 5 min each, and probed with 1X Detection Antibody Cocktail for 1 h at room temperature with 
gentle agitation. Streptavidin-conjugated HRP along with LumiGLO®/Peroxide Reagent were used to visualise 
the bound antibody cocktail by chemiluminescence. ChemiDoc™ MP Imaging System with Image Lab™ software 
was used to capture images of the slide. The Protein Array Analyzer114 for Image J (National Institutes of Health, 
Bethesda, Maryland, USA) was used for the densitometric analysis. The relative peak intensities of the examined 
signalling molecules were normalised to the corresponding values of the positive and negative controls of the 
array.
Immunocytochemistry. 1×105 cells per well were grown on the Millicell EZ SLIDE eight-well glass 
chamber slides for 24 h. Following serum starvation for 8 h, cells were stressed with 100 nM of thapsigargin for 
16 h, in the presence or absence of 100nM of Liraglutide. Thereafter, cells were washed once with 1X PBS, fixed 
with 4% paraformaldehyde for 10 min and permeabilised in 0.3% Triton-X-100 for 5 min at room temperature. 
Cells were blocked in 10% normal goat serum and incubated with the primary antibody against Nrf2 (1:500) 
or ATF6 (1:200) overnight at 4 C. Primary antibody was diluted in 1% BSA in 1X PBS supplemented with 0.3% 
Triton-X-100. Following primary antibody incubation, cells were washed three times in 1X PBS for 5 min each 
and incubated with goat anti-rabbit IgG H & L Alexa Fluor® 488 secondary antibody (1:1000) for 1 h at room 
temperature. Specimens were cover-slipped with Vectashield Antifade Mounting Medium with DAPI (Vector 
Laboratories Ltd, Cambridgeshire, UK) and sealed with nail polish. Zeiss LSM510 Meta Laser Scanning confocal 
microscope was used for cell imaging and eight pictures were captured per experimental group per experiment 
for quantification. Image J was used to quantify Nrf2 corrected total cell fluorescence (CTCF) in the cell nucleus. 
Image acquisition and processing were performed in a blinded fashion.
Statistics. All the results were expressed as mean ± standard error (SEM) of at least three independent exper-
iments for each group. Differences among means were considered significant if p ≤ 0.05. Data was processed 
with one way ANOVA analysis, followed by post hoc Bonferroni’s multiple-comparison t-tests to identify differ-
ences among groups of unstressed and stressed conditions. The effects of Liraglutide were studied by two way 
ANOVA, followed by post hoc Bonferroni’s multiple-comparison t-tests. Statistical calculations were performed 
in GraphPad Prism 5 (GraphPad Software Inc., San Diego, USA) for Mac OS X software.
Data availability. The data supporting the findings of this study are included in this published article and 
its supplementary information file. All datasets generated during the current study are available from the corre-
sponding author (C.H.) on reasonable request.
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